Typical antipsychotics

38,344views

Typical antipsychotics

Watch later

Watch later

Hypertension: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Myocardial infarction
Patent ductus arteriosus
Pericarditis and pericardial effusion
Peripheral artery disease
Pleural effusion
Pneumonia
Pulmonary edema
Restrictive lung diseases
Shock
Stroke volume, ejection fraction, and cardiac output
Tetralogy of Fallot
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Cranial nerves
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Abnormal uterine bleeding: Clinical
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Primary adrenal insufficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Testosterone
Thyroid hormones
Benign prostatic hyperplasia
Congenital adrenal hyperplasia
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal cortical carcinoma
Conn syndrome
Thyroglossal duct cyst
Hyperthyroidism
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Euthyroid sick syndrome
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Riedel thyroiditis
Thyroid cancer
Hyperparathyroidism
Hypoparathyroidism
Hypercalcemia
Hypocalcemia
Diabetes mellitus
Diabetic retinopathy
Diabetic nephropathy
Hyperpituitarism
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Gigantism
Acromegaly
Hypopituitarism
Pituitary apoplexy
Sheehan syndrome
Hypoprolactinemia
Constitutional growth delay
Diabetes insipidus
Precocious puberty
Delayed puberty
Premature ovarian failure
Androgen insensitivity syndrome
Kallmann syndrome
5-alpha-reductase deficiency
Autoimmune polyglandular syndrome type 1 (NORD)
Multiple endocrine neoplasia
Pancreatic neuroendocrine neoplasms
Zollinger-Ellison syndrome
Carcinoid syndrome
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Vaccinations
Acute cholecystitis
Acne vulgaris
Opioid antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Vitamin B12 deficiency
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Adrenergic antagonists: Beta blockers
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class III antiarrhythmics: Potassium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Anthelmintic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Anti-parkinson medications
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Headaches: Clinical
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Folate (Vitamin B9) deficiency

Transcript

Watch video only

Antipsychotics, as their name implies, are mainly used to treat schizophrenia and other psychotic conditions. Even though the exact cause of schizophrenia is still unknown, there's some evidence that suggests it’s related to altered levels of the neurotransmitter dopamine. Now, antipsychotics are subdivided into two main categories: the first generation or typical antipsychotics, and the second generation or atypical antipsychotics.

Alright, within the brain, dopamine is found in 4 main dopamine pathways: the mesolimbic pathway, which controls motivation and desire; the mesocortical pathway, which helps regulate emotions; the nigrostriatal pathway, which contains motor neurons that bypass the medullary pyramids, to control involuntary movements and coordination; and lastly, the tuberoinfundibular pathway, which releases dopamine to limit the secretion of prolactin. Other regions of the central nervous system that are rich in dopamine receptors include the chemoreceptor trigger zone, which initiates the vomiting reflex, and the medullary periventricular pathway, which regulates eating behavior.

However, in schizophrenia, altered levels of dopamine mainly affect the mesolimbic pathway and mesocortical pathway. There’s usually high levels of dopamine in the mesolimbic pathway which cause positive symptoms of schizophrenia, such as delusions, hallucinations, and disorganized thought. On the other hand, low levels of dopamine in the mesocortical pathway cause negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and “flat affect,” which basically means a lack of emotions.

When it comes to treating schizophrenia, some typical antipsychotics like haloperidol, trifluoperazine, and fluphenazine have a higher potency, which means you need less of it to achieve a therapeutic effect. The lower potency antipsychotics include thioridazine and chlorpromazine and they require larger doses to achieve the same therapeutic effect as high-potency antipsychotics.

Now, in conditions such as schizophrenia, typical antipsychotics block dopamine D2 receptors in the mesolimbic pathway, which alleviates positive symptoms of schizophrenia. However, they also block dopamine receptors in the mesocortical pathway, which might actually worsen the negative symptoms.

Other psychiatric indications include psychosis, delirium, bipolar disorder, obsessive-compulsive disorder, Tourette syndrome, and Huntington disease. Aside from their use in psychiatric disorders, blocking dopamine receptors in the chemoreceptor trigger zone can also decrease nausea and vomiting, while blocking histamine H1 receptors can have an antipruritic and sedative effect.

Alright, moving on to side effects. In the tuberoinfundibular pathway, they stimulate the release of prolactin, causing oligomenorrhea, galactorrhea, and gynecomastia; and lastly, in the nigrostriatal pathway, they cause extrapyramidal symptoms, which usually involve abnormal movements.

Let’s start with dystonia, which can occur within a few hours to days of treatment, and includes muscle spasms of the tongue, face, neck, and back. It also causes oculogyric crisis, which is a spasm of the extraocular muscles, causing an upward and outward position of the eyes. After a few days to a month, there could be Akathisia or pseudoparkinsonism. Akathisia is characterized by restlessness and an urge to move the limbs. Pseudoparkinsonism is characterized by muscle rigidity, usually in the facial muscles, giving the face a wooden, mask-like appearance. Other symptoms include bradykinesia, or slow movements, and tremors. It’s important to note that typical antipsychotics are more likely to cause these side effects compared to the atypical antipsychotics. However, extrapyramidal symptoms usually disappear once the medication is stopped.

Now, moving on to tardive dyskinesia, which can present after several months or even years; is characterized by constant involuntary, rhythmic movements. This typically happens with the perioral muscles causing the person to repeatedly smack, or purse their lips. Unlike acute extrapyramidal symptoms, tardive dyskinesia can be irreversible, so the medication should be discontinued at the first sign of tardive dyskinesia.

Key Takeaways

Typical antipsychotics, also known as first-generation antipsychotics, are a class of medications used to treat various psychiatric disorders, particularly schizophrenia and other psychotic disorders. They work by blocking dopamine D2 receptors in the mesolimbic pathway in the brain, which helps to reduce the symptoms of psychosis.

Typical antipsychotics include medications such as chlorpromazine, haloperidol, and fluphenazine. These medications are generally effective at reducing positive symptoms of psychosis, such as hallucinations and delusions, but may have limited effectiveness for negative symptoms and may also cause significant side effects.

Common side effects of typical antipsychotics include extrapyramidal symptoms, such as tremors and muscle rigidity, as well as weight gain, sedation, and sexual dysfunction. Long-term use of these medications may also be associated with a higher risk of developing tardive dyskinesia, a movement disorder characterized by involuntary muscle movements.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic Malignant Syndrome" Annals of Pharmacotherapy (2016)
  5. "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" The Lancet (2009)
  6. "Update on Typical and Atypical Antipsychotic Drugs" Annual Review of Medicine (2013)